SCHEMBL19829889

SCHEMBL19829889

CC(=O)NC1C(OC2C(O)C(CO)OC(OC3C(CO)OC(OC4C(CO)OC(OCCCCCN)C(O)C4O)C(O)C3O)C2O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1OC1OC(C)C(O)C(O)C1O

nearest known ligand 0.60

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LGALS8 O00214 2/20 0.60
LGALS3 P17931 2/20 0.60
LGALS4 P56470 2/20 0.60
MAPK1 P28482 1/20 0.49
IFNG P01579 1/20 0.46
FGF1 P05230 1/20 0.46
FGF2 P09038 1/20 0.46
BMP2 P12643 1/20 0.46
VEGFA P15692 1/20 0.46
SFRP1 Q8N474 1/20 0.46
IGF2R P11717 2/20 0.45
CD209 Q9NNX6 2/20 0.45
SELL P14151 3/20 0.44
PTN P21246 1/20 0.43
MDK P21741 1/20 0.43
BDNF P23560 1/20 0.43
SIGLEC7 Q9Y286 2/20 0.42
SELP P16109 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18011565 1.00 LGALS8 (0.60) LGALS8LGALS3LGALS4MAPK1IFNG
SCHEMBL15479618 1.00 LGALS8 (0.60) LGALS8LGALS3LGALS4MAPK1IFNG
SCHEMBL13541636 1.00 LGALS8 (0.60) LGALS8LGALS3LGALS4MAPK1IFNG
SCHEMBL15482022 1.00 LGALS8 (0.60) LGALS8LGALS3LGALS4MAPK1IFNG
SCHEMBL19404896 0.96 LGALS8 (0.56) LGALS8LGALS3LGALS4MAPK1IFNG
SCHEMBL19404889 0.96 LGALS8 (0.56) LGALS8LGALS3LGALS4MAPK1IFNG
SCHEMBL22180459 0.96 LGALS8 (0.56) LGALS8LGALS3LGALS4MAPK1IFNG
SCHEMBL19398495 0.96 LGALS8 (0.56) LGALS8LGALS3LGALS4MAPK1IFNG
SCHEMBL29374092 0.96 LGALS8 (0.59) LGALS8LGALS3LGALS4MAPK1IFNG
SCHEMBL19398457 0.96 LGALS8 (0.65) LGALS8LGALS3LGALS4MAPK1IFNG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11642400-B2 Immunogenic/therapeutic glycan compositions and uses thereof OBI PHARMA, INC. (TW) 2023-05-09 US disclosed
US-20180028629-A1 IMMUNOGENIC/THERAPEUTIC GLYCAN COMPOSITIONS AND USES THEREOF OBI PHARMA, INC. (TW) 2018-02-01 US disclosed
US-20180028629-A1 IMMUNOGENIC/THERAPEUTIC GLYCAN COMPOSITIONS AND USES THEREOF OBI PHARMA, INC. (TW) 2018-02-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11642400-B2 Immunogenic/therapeutic glycan compositions and uses thereof OGA, FUT4, B3GAT3 LGALS8 48/4885LGALS3 21/4885LGALS4 6/4885
US-20180028629-A1 IMMUNOGENIC/THERAPEUTIC GLYCAN COMPOSITIONS AND USES THEREOF OGA, FUT4, B3GAT3 LGALS8 48/4885LGALS3 21/4885LGALS4 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.